Cell line · CVCL_H716
Papers33
8 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting the EpCAM-AXL axis to overcome drug resistance in lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Golgi enzymes are retrieved from the plasma membrane to the trans-Golgi network. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The ALS- and FTD-associated proteins annexin A11 and CHMP2B act sequentially in plasma membrane repair. | Dev Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RPA hyperphosphorylation hinders the resolution of R-loops and G-quadruplex-associated R-loops during RAS-driven senescence. | Nucleic Acids Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrating natural and engineered genetic variations to decode regulatory influence on blood traits. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Obesity promotes urinary tract infection by disrupting bladder focal adhesion kinase signaling. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Post-transcriptional control of KRAS: functional roles of 5'UTR RNA G-quadruplexes, long noncoding RNA, and hnRNPA1. | Nucleic Acids Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epitope and HLA specificity of human TCRs against Plasmodium falciparum circumsporozoite protein. | J Exp Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. | Nat Cell Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The MYC-NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_H716/papers